Recent advances of autologous stem cell transplant in malignant lymphoma
- VernacularTitle:恶性淋巴瘤自体造血干细胞移植后复发的研究进展
- Author:
Jihong YANG
;
Yaping YU
;
- Publication Type:Journal Article
- Keywords:
Autologous stem cell transplant;
Malignant lymphomai;
Riluximab;
Involved field radiation therapy
- From:
Journal of Medical Postgraduates
2003;0(09):-
- CountryChina
- Language:Chinese
-
Abstract:
Autologous stem cell transplant (ASCT) is a potentially curative therapy for patients with relapsed and refractory or aggressive non Hodgkin ' s lymphoma, relapse is still common and is caused by high levels of tumour cell burden in the host and contamination of the stem cells with tumour cell. To improve effect of ASCT, ① in vivo puring with riluximab in pre transplant, depletion of B cells from the peripheral blood and clear the contamination of the malignant cells; ②the combination chemotherapy replace with rilumixab and non cross resistance drug in post transplant, killing tumour cells in the host; (3)involved field radiation therapy(IFRT) as a adjunct to pre or post transplant, reducing the relapse rate.
